Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2
|
|
- Stephany Sims
- 5 years ago
- Views:
Transcription
1 Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2 Guido Engelmann, MD a, Daniel Wenning, MD b, Diran Herebian, PhD c, Oliver Sander, MD d, Carola Dröge e, Stefanie Kluge, PhD e, Ralf Kubitz, MD e,f Mutations in the gene encoding the canalicular bile salt export pump (BSEP) can result in progressive familial intrahepatic cholestasis type 2 (PFIC-2). Treatment options are limited,andpfic-2oftennecessitates liver transplantation. We report on a young woman and a boy who clinically presented with PFIC-2 phenotypes and dramatically improved with steroid treatment. Gene sequencing of ABCB11 encoding for BSEP revealed 2 relevant mutations in both patients. The young woman was compound heterozygous for p.t919del and p.r1235x. At the age of 5 years, partial biliary diversion was performed and rescued liver function but left serum bile salt levels elevated. At age 23 she developed systemic lupus erythematosus. Unexpectedly, steroid therapy normalized serum bile salt levels, with a strong correlation with the steroid dose. She is currently in clinical remission. The boy was compound heterozygous for the ABCB11 mutations c.150+3a.c and p.r832c and presented with intractable pruritus. When he developed colitis, he was treated with steroids. The pruritus completely disappeared and relapsed when steroids were withdrawn. To date, with low-dose budesonide, the boy has been symptom-free for.3 years. In conclusion, the clinical courses suggestthatpatientswithbsepdeficiency and residual BSEP activity may benefit from steroid-based therapy, which represents a new treatment option. Familial intrahepatic cholestasis syndromes comprise a group of liver diseases that are caused by the failure of hepatobiliary transporter proteins. Certain mutations in the ABCB11 gene 1 3 lead to deficient expression of the canalicular bile salt export pump (BSEP), causing hepatocellular bile salt (BS) accumulation and subsequent liver cirrhosis. The residual transport activity of BSEP inversely correlates with the severity of the patient s phenotype. Complete absence of BSEP activity is associated with progressive familial intrahepatic cholestasis type 2 (PFIC-2). Patients with PFIC-2 suffer from continuously evolving pruritus, wasting jaundice, and sequelae of liver cirrhosis, often necessitating liver transplantation 4 in early childhood. In large studies, PFIC represented 10% to 15% of causes of childhood cholestasis and is the reason for up to 15% of liver transplantations in children. Treatment focuses on symptom relief and normalization of liver function tests. It is based on ursodeoxycholic acid (UDCA), with improvement of symptoms in 75% of cases, 5,6 rifampicin, and partial biliary diversion. We here report on 2 patients with PFIC-2 phenotypes and sustained clinical relief of symptoms and unexpected improvement in hypercholemia in response to oral steroids. abstract a Department of Pediatrics, Lukashospital, Neuss, Germany; b Department of General Pediatrics, University Hospital Heidelberg, Ruprecht-Karls-University, Heidelberg, Germany; Departments of c General Pediatrics, Neonatology and Pediatric Cardiology, d Rheumatology, and e Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Heinrich-Heine-University, Düsseldorf, Germany; and f Medical Clinic I, Bethanien Hospital, Moers, Germany Drs Engelmann and Wenning treated one of the patients, conceptualized and designed the study, and drafted the initial manuscript; Dr Herebian carried out biochemical analysis; Dr Sander treated one of the patients, coordinated clinical data collection, and critically reviewed the manuscript; Ms Dröge and Drs Kluge and Kubitz carried out the biochemical and genetic analyses, collected clinical data, and reviewed and revised the manuscript; and all authors approved the final manuscript as submitted. DOI: /peds Accepted for publication Feb 4, 2015 Address correspondence to Guido Engelmann, MD, Lukashospital, Department of Pediatrics, Preussenstrasse 84, D Neuss, Germany. engelmann@lukasneuss.de PEDIATRICS (ISSN Numbers: Print, ; Online, ). Copyright 2015 by the American Academy of Pediatrics FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose. FUNDING: No external funding. POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose. PEDIATRICS Volume 135, number 5, May 2015 CASE REPORT
2 PATIENT PRESENTATION Patient 1 A girl (born 1989) presented with vitamin K deficiency (8 weeks of age), pruritus (8 months), followed by jaundice (10 months) with a BS concentration of 583 mmol/l (normal:,8 mmol/l). Aminotransferases and gamma-glutamyl transferase were normal. A liver biopsy revealed severe intrahepatic cholestasis and PFIC-2 was suspected. UDCA treatment was started, and a partial external biliary diversion procedure was performed at theageof5years,whichledtogood control of pruritus for 15 years. Sequencing of ABCB11 (BSEP) revealed compound heterozygosity for the deletion of a coding triplet (c.2756_2758delcca), resulting in the loss of a single threonine at amino acid position 919 (p.t919del, inherited by the mother) and the non-sense mutation c.3703c.t/p. R1235X, resulting in a premature stop-codon at amino acid position 1235 (inherited by the father) (Fig 1). The initial liver biopsy revealed an apparently normal expression of BSEP (Fig 1). The anti-bsep antibody, which was used for immunofluorescence, was directed against the 13 C-terminal amino acids of BSEP. 7 BSEP immunoreactivity in the patient s liver biopsy sample must therefore have been due to expression of the allele carrying the T919del variant, because in the presence of p.r1235x (premature stop codon) the 86 C-terminal amino acids are lacking. At the age of 23 years the patient s general condition deteriorated, and she presented with polyarthritis, polyserositis, splenomegaly, anemia, leukocytopenia, and pruritus. Antinuclear antibody titer was.1: 5120, and anti-double-strandeddna antibodies were 6738 U/mL (ELISA). Systemic lupus erythematosus was diagnosed. Treatment was started with prednisolone at a dose of 30 mg/day followed by complete symptom relief. Serositis recovered, and the arthritis improved thereafter. Steroids were tapered to 7.5 mg/day, with a flare up of arthritis and increasing anti-double-strandeddna antibodies to 4549 U/mL. Prednisolone was increased to 15 mg/day, once again resulting FIGURE 1 Immunofluorescence of liver tissue and DNA sequencing in patient 1. Liver tissue of patient 1 (taken at the age of 10 months) reveals a clear canalicular staining pattern for BSEP and MRP2 (scale bar = 10 mm), as visualized by immunofluorescent staining and confocal laser scanning microscopy. The young woman is compound heterozygous for a triplet deletion in exon 21 c.2756_2758delcca (p.t919del) and a non-sense mutation c.3703c.t (p.r1235x) in coding exon 26 of ABCB11. Sequences are shown on the nucleotide and protein level. 2 ENGELMANN et al
3 FIGURE 2 Serum BS and bilirubin levels in correlation with steroid therapy in patient 1. Upper panel: (1) steroid therapy (30 mg/day) led to normalized BS levels and a decline in bilirubin; (2) dose reduction to 15 mg/day resulted in slightly increased BSs; (3) further reduction to 7.5 mg/day entailed a distinct increase in BSs; (4) redoubling the dose led again to a decrease in BSs. Lower panel: BSs were measured in serum and bile before (2009) and during (2012) steroid therapy. Although BS concentration in serum decreased by a factor of 4.5, the concentration in bile (collected from the biliostoma) increased by a factor of 6.2, from 1.5 to 9.6 mmol/l, suggesting a strong stimulation of bile acid secretion during steroid therapy. in clinical improvement in arthritis and pruritus. Serum BS levels normalized during the initial higher dose of systemic steroid therapy (Fig 2). Interestingly, total BS concentration in bile collected from the partial external biliary diversion increased to 9.56 mmol/l (August 2012) compared with 1.53 mmol/l before steroid treatment (May 2009). Three years after the introduction of steroids (November 2011), she is still free of symptoms of cholestasis. Patient 2 Patient 2 (born 2004) presented at an age of 2.5 years with severe pruritus despite adequate therapy with rifampicin, phenobarbital, and naloxone; interrupted night sleep; and fatigue. Blood examinations revealed a mild cholestasis with total bilirubin of 23.4 mmol/l and direct bilirubin of 9 mmol/l. Serum BS concentration was mmol/l, whereas aminotransferases, gammaglutamyl-transferase, alkaline phosphatase, and cholesterol were within normal ranges. PFIC-2 was suspected, and a liver biopsy was obtained. Histology revealed chronic cholestasis, disorganization of portal structures, and degenerative bile duct alterations. Treatment with UDCA and naltrexon improved pruritus. At the age of 4.5 years pruritus and jaundice worsened, with a direct bilirubin of 230 mmol/l. In addition, diarrhea and painful bowel movements developed. Endoscopic retrograde cholangiography revealed no evidence of primary sclerosing cholangitis but showed a secretion of pale-appearing bile. On colonoscopy, a left-sided colitis with superficial granulocyte infiltration of the mucosa in the proximal parts of the colon was diagnosed. Genetic analysis revealed mutations in the ABCB11 gene. In the 20th coding exon a heterozygotic missense mutation c.2494c.t (p.r832c, inherited by the mother) was detected together with the heterozygotic splice site mutation c.150+3a.c distally to exon3(inheritedbythefather).no mutations of the ATP8B1 gene or of the JAG1 gene (Alagille syndrome) were detected. Immunofluorescence revealed normal distribution of BSEP and of the bilirubin transporter multidrug resistance-associated protein 2 (MRP 2) used as a canalicular marker (Fig 3). The course of the disease was progressive, with increasing hepatomegaly and advancing liver fibrosis (FibroScan [Echosense, Paris, France] was 10.4 kpa at the age of 4.75 years and 14.6 kpa at the age of 5 years). The patient was listed for liver transplantation and a living related transplantation was considered. The administration of prednisolone led to relief of the diarrhea and pruritus. BSs and bilirubin normalized completely (Fig 4). Budesonide had the same benefit but without side effects. Liver stiffness improved to almost normal values 8 (6.3 kpa, age 7 years). The patient was taken off the transplant list and is currently free of symptoms (as of 2014). DISCUSSION We here report on complete symptom relief and sustained normalization of PEDIATRICS Volume 135, number 5, May
4 FIGURE 3 Immunofluorescence of liver tissue and DNA sequencing in patient 2. BSEP and MRP2 show a clear canalicular and a weak basolateral hepatocyte staining (scale bar = 10 mm) as uncovered by immunofluorescence and confocal laser scanning microscopy. Patient 2 and his brother (our patient s younger brother with the same phenotype but much lesser symptoms has not been treated with steroids so far) are compound heterozygous for the splice site mutation c.150+3a.c in intervening sequence 4 (IVS4) and the missense mutation c.2494c.t (p.r832c) in ABCB11 coding exon 20. Sequences are shown on the nucleotide and protein level. liver function tests in 2 unrelated patients with PFIC-2 phenotypes. In most PFIC-2 patients, BSEP expression is absent or severely reduced in liver tissue. 9 However, our patients showed clear immunoreactivity for BSEP in their livers. Detection of significant amounts of BSs (between 1.5 and 9.5 mmol/l) in the bile of patient 1 suggests residual BSEP activity, which may be an important requirement for successful steroid therapy. It is believed that the extent of expression inversely correlates with phenotype severity (reviewed in ref 10), with some exceptions. 5 In patient 2, the course of liver and intestinal disease could be positively influenced by prednisolone. Tapering of prednisolone was associated with worsening of cholestasis and intestinal disease. Eventually, budesonide at a minimal effective dosage of 3 mg every second day resulted in complete clinical and biochemical remission within 6 months for.3 years. The mechanism of action of the steroids in the context of PFIC-2 is 4 ENGELMANN et al
5 FIGURE 4 Progression of serum BS concentrations in patient 2. Prednisolone (Pred) administration was started at 2 mg/kg per day. Decreasing dosages of prednisolone led to an increase in BS concentrations. Repetitive prednisolone treatment improved serum BS concentrations. Treatment with azathioprine (Aza; 2 mg/kg) and methotrexate (MTX; 15 mg/m 2 ) were inefficient. Budesonide (Bud; 6 mg/day) induced a sustained remission. not yet clear but could possibly involve upregulation of BSEP transporter activity, although experimental data are conflicting. In primary rat hepatocytes, BSEP-mRNA as well as Mrp2-mRNA and protein expression were upregulated by dexamethasone in a concentrationdependent manner In line with this finding, treatment of rats with glucocorticoids including budesonide was associated with the upregulation of BSEP, Mrp2, and cytochrome P450 oxidase. 14 On the other hand, Liu et al 15 showed that dexamethasone administration to neonatal rats in vivo had a stimulating effect on Mdr2 (the ortholog to the human MDR3) and Na + -taurocholate cotransporting polypeptide (Ntcp) gene expression, but decreased the gene expression of Bsep, Mrp2, and Fic1, a P-type ATPase protein. However, most differences were not significant in that study. The effect of steroids on canine bile flow has been demonstrated by Brems et al. 16 Dogs given high dosages of hydrocortisone at 5 mg/kg per hour showed a significant increase in bile flow (from 258 ml/minute to 357 ml/minute) independent of BS concentration. The ABCB11 splice site mutation c.150+3a.c results in partial exon skipping of exon 3 in vivo, and approximately one-third of mrna transcripts are correctly spliced (C.D., R.K., D.H., unpublished data). Therefore, in patient 2, steroids may upregulate transcription and could potentially improve correct mrna splicing or recover transport activity of BSEP R832C. Another steroid-dependent mechanism of regulated BS transport may involve Na + -dependent cellular bile acid uptake via NTCP, which is localized at the sinusoidal membrane of hepatocytes. 17 It has been shown that, under cholestatic conditions such as biliary atresia, 18 inflammation-induced cholestasis, 19,20 primary biliary cirrhosis, 21 or progressive familial intrahepatic cholestasis, 22 NTCP is downregulated in human livers. This downregulation may serve to protect hepatocytes from toxic BS concentration but may contribute to the retention of BSs in the blood under cholestatic conditions. An essential glucocorticoid response element (GRE) has been identified within the NTCP promoter at a nucleotide position of 232 to 212 relative to the transcription start site. 23 Therefore, glucocorticoids may improve transepithelial BS transport by upregulation of NTCP, providing an increased gradient for BSEP, thus counteracting cholestasis. Budesonide is a steroid with rapid intestinal reabsorption and a high first-pass clearance of 90%. 24,25 Special formulations of budesonide, however, may reach the distal colon. 26 In line with this, colitis in patient 2 remained in remission under alternating dosages of 3 mg budesonide. It is possible that cholestasis might be perpetuated due to extrahepatic inflammation as the primary insult. On the other hand, patient 1 had a slight decrease in BS coincident with active systemic lupus erythematosus even before initiation of steroid therapy. It is well known that lipopolysaccharides induce cholestasis 27 and downregulate BSEP in a model of human liver slices. 19 However, primary sclerosing PEDIATRICS Volume 135, number 5, May
6 cholangitis in the context of ulcerative colitis in general is not sensitive to steroid therapy, 28,29 a fact that demonstrates the completely different pathomechanisms of BSEP deficiency and primary sclerosing cholangitis. Clearly, steroid therapy in patients with PFIC is only indicated if prompt effect (within 4 weeks) is detected because the steroid therapy itself has relevant side effects if given for a long time. 30 To our knowledge, this is the first clinical report in which, in vivo, a beneficial effect of steroid administration on the disease course of BSEP deficiency/pfic-2 was shown. For future patient management it would be worth further classifying the PFIC population via genetic analysis, immunohistochemistry or immunofluorescence, and clinical profile to determine those patients who would benefit from steroid administration. REFERENCES 1. Thompson R, Strautnieks S. BSEP: function and role in progressive familial intrahepatic cholestasis. Semin Liver Dis. 2001;21(4): Strautnieks SS, Bull LN, Knisely AS, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20(3): Plass JRM, Mol O, Heegsma J, et al. A progressive familial intrahepatic cholestasis type 2 mutation causes an unstable, temperature-sensitive bile salt export pump. J Hepatol. 2004;40(1): Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis. 2009;4:1 5. Stindt J, Ellinger P, Weissenberger K, et al. A novel mutation within a transmembrane helix of the bile salt export pump (BSEP, ABCB11) with delayed development of cirrhosis. Liver Int. 2013;33(10): Davit-Spraul A, Fabre M, Branchereau S, et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010;51(5): Gerloff T, Stieger B, Hagenbuch B, et al. The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver. J Biol Chem. 1998; 273(16): Engelmann G, Gebhardt C, Wenning D, et al. Feasibility study and control values of transient elastography in healthy children. Eur J Pediatr. 2012;171(2): Strautnieks SS, Byrne JA, Pawlikowska L, et al. Severe bile salt export pump deficiency: 82 different ABCB11 mutations in 109 families. Gastroenterology. 2008;134(4): Kubitz R, Dröge C, Stindt J, Weissenberger K, Häussinger D. The bile salt export pump (BSEP) in health and disease. Clin Res Hepatol Gastroenterol. 2012;36(6): Warskulat U, Kubitz R, Wettstein M, Stieger B, Meier PJ, Häussinger D. Regulation of bile salt export pump mrna levels by dexamethasone and osmolarity in cultured rat hepatocytes. Biol Chem. 1999;380(11): Kubitz R, Warskulat U, Schmitt M, Häussinger D. Dexamethasone- and osmolarity-dependent expression of the multidrug-resistance protein 2 in cultured rat hepatocytes. Biochem J. 1999;340(pt 3): Fardel O, Payen L, Courtois A, Vernhet L, Lecureur V. Regulation of biliary drug efflux pump expression by hormones and xenobiotics. Toxicology. 2001;167(1): Rosales R, Romero MR, Vaquero J, et al. FXR-dependent and -independent interaction of glucocorticoids with the regulatory pathways involved in the control of bile acid handling by the liver. Biochem Pharmacol. 2013;85(6): Liu Y, Havinga R, VAN DER Leij FR, et al. Dexamethasone exposure of neonatal rats modulates biliary lipid secretion and hepatic expression of genes controlling bile acid metabolism in adulthood without interfering with primary bile acid kinetics. Pediatr Res. 2008;63(4): Brems JJ, Reese J, Kane R III, Kaminski DL. Effect of cyclosporine and steroids on canine bile flow. Hepatology. 1991;14(3): Cheng X, Buckley D, Klaassen CD. Regulation of hepatic bile acid transporters Ntcp and Bsep expression. Biochem Pharmacol. 2007;74(11): Shneider BL, Fox VL, Schwarz KB, et al. Hepatic basolateral sodium-dependentbile acid transporter expression in two unusual cases of hypercholanemia and in extrahepatic biliary atresia. Hepatology. 1997;25(5): Elferink MGL, Olinga P, Draaisma AL, et al. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process. Am J Physiol Gastrointest Liver Physiol. 2004; 287(5):G1008 G Zollner G, Fickert P, Zenz R, et al. Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. Hepatology. 2001;33(3): Kojima H, Nies AT, König J, et al. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol. 2003;39(5): Keitel V, Burdelski M, Warskulat U, et al. Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis. Hepatology. 2005;41(5): Eloranta JJ, Jung D, Kullak-Ublick GA. The human Na+-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor-gamma coactivator-1alpha, and suppressed by bile acids via a small heterodimer partner-dependent mechanism. Mol Endocrinol. 2006;20(1): Benchimol EI, Seow CH, Otley AR, Steinhart AH. Budesonide for maintenance of remission in Crohn s disease. Cochrane Database Syst Rev. 2009; (1):CD Otley A, Steinhart AH. Budesonide for induction of remission in Crohn s disease. Cochrane Database Syst Rev. 2005;4:CD ENGELMANN et al
7 26. Kolkman JJ, Möllmann HW, Möllmann AC, et al. Evaluation of oral budesonide in the treatment of active distal ulcerative colitis. Drugs Today (Barc). 2004;40(7): Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(10): Treeprasertsuk S, Björnsson E, Sinakos E, Weeding E, Lindor KD. Outcome of patients with primary sclerosing cholangitis and ulcerative colitis undergoing colectomy. World J Gastrointest Pharmacol Ther. 2013;4(3): MacLean AR, Lilly L, Cohen Z, O Connor B, McLeod RS. Outcome of patients undergoing liver transplantation for primary sclerosing cholangitis. Dis Colon Rectum. 2003;46(8): Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids new mechanisms for old drugs. N Engl J Med. 2005;353(16): PEDIATRICS Volume 135, number 5, May
8 Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2 Guido Engelmann, Daniel Wenning, Diran Herebian, Oliver Sander, Carola Dröge, Stefanie Kluge and Ralf Kubitz Pediatrics originally published online April 6, 2015; Updated Information & Services Permissions & Licensing Reprints including high resolution figures, can be found at: Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: Information about ordering reprints can be found online:
9 Two Case Reports of Successful Treatment of Cholestasis With Steroids in Patients With PFIC-2 Guido Engelmann, Daniel Wenning, Diran Herebian, Oliver Sander, Carola Dröge, Stefanie Kluge and Ralf Kubitz Pediatrics originally published online April 6, 2015; The online version of this article, along with updated information and services, is located on the World Wide Web at: Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, Copyright 2015 by the American Academy of Pediatrics. All rights reserved. Print ISSN:
Hepatic Transporter Proteins involved in Bile Formation
Bile salt synthesis Hepatic Transporter Proteins involved in Bile Formation Basolateral membrane transporter proteins fx: NTCP uptake of bile salts OATP bulky organic anions Canalicular membrane transporter
More informationOverview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN
Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN 2012 Annual Conference PSC Partners Seeking a Cure May 5, 2012 Primary Sclerosing Cholangitis Multifocal
More informationTREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC)
TREATMENT OF PRIMARY BILIARY CIRRHOSIS (PBC) URSO not indicated Therapy for PBC Difficulties Etiology is uncertain Therapies are based on ideas regarding pathogenesis Present medical therapies have a limited
More informationDhanpat Jain Yale University School of Medicine, New Haven, CT
Dhanpat Jain Yale University School of Medicine, New Haven, CT Case history 15 years old female presented with fatigue. Found to have features suggestive of cirrhosis with esophageal varices, splenomegaly
More informationPROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
The Childhood Liver Disease Research Network strives to provide information and support to individuals and families affected by liver disease through its many research programs. PROGRESSIVE FAMILIAL INTRAHEPATIC
More informationAutoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP
Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP Autoimmune hepatobiliary diseases The liver is an important target for immunemediated injury. Three disease phenotypes are recognized:
More informationDiagnosis and Management of PBC
Diagnosis and Management of PBC Cynthia Levy, MD, FAASLD University of Miami Miller School of Medicine Miami, Florida 1 Primary Biliary Cholangitis (PBC) Chronic cholestatic liver disease Autoimmune in
More informationGenetic cholestasis. Peter Jansen Liver Center Academic Medical Center Amsterdam
Genetic cholestasis Peter Jansen Liver Center Academic Medical Center Amsterdam Genetic cholestasis Proteins and genes Genetic cholestatic diseases Lessons from ko/mutant models A new MDR3 phenotype A
More informationCase Report. Introduction
Relapsing features of bile salt export pump deficiency after liver transplantation in two patients with progressive familial intrahepatic cholestasis type 2 Giuseppe Maggiore 1,2,, Emmanuel Gonzales 3,7,,
More informationFalk Symposium 156: Genetics in Liver Disease. Pharmacogenetics. Gerd Kullak-Ublick
Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics Gerd Kullak-Ublick Division of Clinical Pharmacology and Toxicology Department of Internal Medicine University Hospital Zurich Freiburg, 8.
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationCurrent Concepts in the Management and Treatment of PBC & PSC
Current Concepts in the Management and Treatment of PBC & PSC Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London A family affair? Central vein Hepatocytes
More informationJorge A. Bezerra, M.D.
Improving clinical practice through research: Where are we going? Jorge A. Bezerra, M.D. Conflict of interests Molecular Genetics Laboratory, CCHMC Research funding Gilead Principal Investigator: Anti-HBV
More informationPathophysiology of Bile Secretion
Pathophysiology of Bile Secretion Martin C. Carey, D.Sc., M.D. Division of Gastroenterology, Brigham and Women s Hospital and Department of Medicine, Harvard Medical School Boston, MA, U.S.A. Functions
More informationChronic Cholestatic Liver Diseases
Chronic Cholestatic Liver Diseases - EASL Clinical Practice Guidelines - Rome, 8 October 2010 Ulrich Beuers Department of Gastroenterology and Hepatology Tytgat Institute of Liver and Intestinal Research
More informationPrimary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants
Primary Sclerosing Cholangitis and Cholestatic liver diseases Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants I have nothing to disclose Educational Objectives What is PSC? Understand the cholestatic
More informationPresentation of Progressive Familial Intrahepatic Cholestasis Type 3 Mimicking Wilson Disease: Molecular Genetic Diagnosis and Response to Treatment
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2015.18.3.202 Pediatr Gastroenterol Hepatol Nutr 2015 September 18(3):202-208 Case Report PGHN Presentation of Progressive Familial Intrahepatic
More informationintrahepatic cholestasis type 1. Citation Pediatric Surgery International, 28
NAOSITE: Nagasaki University's Ac Title Author(s) Partial internal biliary diversion intrahepatic cholestasis type 1. Mochizuki, Kyoko; Obatake, Masayuki Akiko; Hayashi, Tomayoshi; Okudaira Citation Pediatric
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationPediatric PSC A children s tale
Pediatric PSC A children s tale September 8 th PSC Partners seeking a cure Tamir Miloh Assistant Professor Pediatric Hepatology Mount Sinai Hospital, NY Incidence Primary Sclerosing Cholangitis (PSC) ;
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France Case 1 52 year-old woman, referred for liver blood tests
More informationNoncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis
Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids Cholestasis Biochemical hallmark Impaired bile flow from liver to small intestine Alkaline phosphatase is primary
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationHangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam
Clinical Aspects of Primary Biliary Cirrhosis Hangzhou, 15 March 2008 Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam Epidemiology of Primary
More informationPrimary Sclerosing Cholangitis Medical Management
Primary Sclerosing Cholangitis Medical Management Kapil Chopra M.D. Assistant Professor of Medicine Division of Transplant Medicine Mayo Clinic Arizona PSC Primary sclerosing cholangitis is a progressive
More informationRegulation of the cell surface expression and transport capacity of BSEP by small chemical molecules
Regulation of the cell surface expression and transport capacity of by small chemical molecules Hisamitsu Hayashi and Yuichi Sugiyama Dept. of Molecular Pharmacokinetics, Graduate School of Pharmaceutical
More informationDrug-induced liver injury
Drug-induced liver injury Vincent Wong MBChB(Hons), MD, FRCP, FHKCP, FHKAM Professor, Department of Medicine and Therapeutics Director, Cheng Suen Man Shook Foundation Centre for Hepatitis Studies Deputy
More informationTHBA Platform - Bile acid imbalance
- Bile acid imbalance Bile acids play an important role in maintaining human health by means of signaling molecules in the regulation of bile formation, liver function and metabolism. The detergent effect
More informationBenign recurrent intrahepatic cholestasis (BRIC) is a rare cause of
original article Description of two new ABCB11 mutations responsible for type 2 benign recurrent intrahepatic cholestasis in a French-Canadian family Yannick Beauséjour MD PhD 1, Fernando Alvarez MD 2,
More informationTreatment of Chronic Cholestasis: What We Know and What We Will Know?
REVIEW Treatment of Chronic Cholestasis: What We Know and What We Will Know? James L. Boyer HISTORICAL PERSPECTIVES For many years, the treatment of cholestatic liver disease was limited to surgical relief
More informationProposal form for the evaluation of a genetic test for NHS Service Gene Dossier
Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier Test Disease Population Triad Disease name OMIM number for disease Disease alternative names please provide any alternative
More informationGrowth analysis in children with PFIC treated with the ASBT inhibitor maralixibat
Growth analysis in children with PFIC treated with the ASBT inhibitor maralixibat INDIGO Study Richard Thompson, Deirdre Kelly, Sanjay Rajwal, Alexander Miethke, Nisreen Soufi, Christine Rivet, Irena Jankowska,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Ocaliva (obeticholic acid) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Ocaliva (obeticholic acid) Prime Therapeutics will review Prior Authorization
More informationAlteration of Bile Acid Transporter Expression in Patients with Early Cholestasis Following Living Donor Liver Transplantation
The Korean Journal of Pathology 2009; 43: 48-55 DOI: 10.4132/KoreanJPathol.2009.43.1.48 Alteration of Bile Acid Transporter Expression in Patients with Early Cholestasis Following Living Donor Liver Transplantation
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis PBC Foundation (UK) Ltd 6 Hill Street Edinburgh EH2 3JZ Tel: +44 (0) 131 556 6811 info@pbcfoundation.org.uk www.pbcfoundation.org.uk PBC for Healthcare Practitioners Introduction
More informationPARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN
PARENTERAL NUTRITION- ASSOCIATED LIVER DISEASE IN CHILDREN Praveen Goday MBBS CNSC Associate Professor Pediatric Gastroenterology Medical College of Wisconsin Milwaukee, WI Parenteral Nutrition-Associated
More informationOverview of PSC Making the Diagnosis
Overview of PSC Making the Diagnosis Tamar Taddei, MD Assistant Professor of Medicine Yale University School of Medicine Overview Definition Epidemiology Diagnosis Modes of presentation Associated diseases
More informationKey Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto
Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective Jenny Heathcote, MD University of Toronto Key Points: AILD comprise autoimmune hepatitis, primary biliary cirrhosis
More informationA Review of Liver Function Tests. James Gray Gastroenterology Vancouver
A Review of Liver Function Tests James Gray Gastroenterology Vancouver Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted
More informationThe best D--- Teaching Case in my Specialty (Henry Appelman Theme) An Elderly Pathologist Tries to Assimilate Molecular Genetics into his Practice
The best D--- Teaching Case in my Specialty (Henry Appelman Theme) Or An Elderly Pathologist Tries to Assimilate Molecular Genetics into his Practice F.Q. 21 yo F (2011) 1998 Age 7 abnormal LFT, high cholesterol
More informationInterval history. It used to be easy (? Easier) 3/12/2012. The best D--- Teaching Case in my Specialty (Henry Appelman Theme) F.Q.
F.Q. 21 yo F (2011) The best D--- Teaching Case in my Specialty (Henry Appelman Theme) Or An Elderly Pathologist Tries to Assimilate Molecular Genetics into his Practice 1998 Age 7 abnormal LFT, high cholesterol
More informationPediatric Primary Sclerosing Cholangitis and Potential Therapies
Pediatric Primary Sclerosing Cholangitis and Potential Therapies Philip Rosenthal, M.D. Professor of Pediatrics & Surgery University of California, San Francisco DISCLOSURE I have the following financial
More informationPBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?
22 November 2018 BD-IAP UK-LPG Liver Update PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features? in a UDCA non-responder Dina G. Tiniakos Institute of Cellular Medicine, Faculty of Medical
More informationBile salt homeostasis is achieved by the coordinate
Expression and Localization of Hepatobiliary Transport Proteins in Progressive Familial Intrahepatic Cholestasis Verena Keitel, 1 Martin Burdelski, 2 Ulrich Warskulat, 1 Thomas Kühlkamp, 1 Dietrich Keppler,
More informationInterpreting Liver Function Tests
PSH Clinical Guidelines Statement 2017 Interpreting Liver Function Tests Dr. Asad A Chaudhry Consultant Hepatologist, Chaudhry Hospital, Gujranwala, Pakistan. Liver function tests (LFTs) generally refer
More informationProlonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters
710 CASE REPORT September-October, Vol. 11 No.5, 2012: 710-714 Prolonged cholestasis triggered by hepatitis A virus infection and variants of the hepatocanalicular phospholipid and bile salt transporters
More informationJaundice. Agnieszka Dobrowolska- Zachwieja, MD, PhD
Jaundice Agnieszka Dobrowolska- Zachwieja, MD, PhD Jaundice definition Jaundice, as in the French jaune, refers to the yellow discoloration of the skin. It arises from the abnormal accumulation of bilirubin
More informationLIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES
LIVER TRANSPLANTATION FOR OVERLAP SYNDROMES OF AUTOIMMUNE LIVER DISEASES No conflict of interest Objectives Introduction Methods Results Conclusions Objectives Introduction Methods Results Conclusions
More informationPrimary Biliary Cholangitis
Primary Biliary Cholangitis What is primary biliary cholangitis? Primary biliary cholangitis (PBC), formerly known as primary biliary cirrhosis, is a chronic liver disease. When a person has PBC, the immune
More informationOral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2016.19.3.210 Pediatr Gastroenterol Hepatol Nutr 2016 September 19(3):210-213 Case Report PGHN Oral Vancomycin Therapy in a Child with Primary
More informationManagement of cholestatic diseases Today and tomorrow
12th Paris Hepatology Conference Management of cholestatic diseases Today and tomorrow Paris 15 January 2019 U. Beuers Department of Gastroenterology & Hepatology Tytgat Institute for Liver and Intestinal
More informationThe many faces of MDR 3 deficiency
The many faces of MDR 3 deficiency Relevance of canalicular membrane transporting proteins for human liver disease Peter LM Jansen and Marleen de Vree Academic Medical Center Amsterdam, The Netherlands
More informationInhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury
Inhibition of Human Hepatic Bile Acid Transporters as Contributing Factors to Drug-Induced Liver Injury Kenneth R. Brouwer, Ph.D., RPh Chief Scientific Officer DDI Meeting June 2017 Seattle, Washington
More informationACG Clinical Guideline: Primary Sclerosing Cholangitis
ACG Clinical Guideline: Primary Sclerosing Cholangitis Keith D. Lindor, MD, FACG 1, Kris V. Kowdley, MD, FACG 2, and M. Edwyn Harrison, MD 3 1 College of Health Solutions, Arizona State University, Phoenix,
More informationSuccessful reactivation of hepatic Mrp transporters in endotoxininduced cholestasis in mice by the CAR activator 6,7-Dimethylesculetin
Successful reactivation of hepatic Mrp transporters in endotoxininduced cholestasis in mice by the activator 6,7-Dimethylesculetin Ina V. Martin *, Sebastian Voigt*, Michael Trauner, Christian Trautwein
More informationNon-infectious hepatic complications in patients with GVHD
Non-infectious hepatic complications in patients with GVHD Tapani Ruutu Helsinki University Central Hospital Liver dysfunction in allogeneic stem cell transplantation injury secondary to the cytoreductive
More informationBiliary tract diseases of the liver
Biliary tract diseases of the liver Digestive Diseases Course Bucharest 2016 Rob Goldin r.goldin@imperial.ac.uk How important are biliary tract diseases? Hepatology 2011 53(5):1608-17 Approximately 16%
More informationApproach to a case of Neonatal Cholestasis
Approach to a case of Neonatal Cholestasis Ira Shah (Co-Incharge, Consultant Pediatrician, Pediatric Liver Clinic) Gunjan Narkhede (Resident in Pediatric Liver Clinic) Pediatric Hepatobiliary Clinic, B.J.Wadia
More informationHépatopathies auto-immunes
16 ème Journée d'automne Lausanne, le 19 octobre 2017 Hépatopathies auto-immunes Nurullah Aslan et Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois
More informationNeonatal Cholestasis. What is Cholestasis? Congenital and Pediatric liver diseases 4/26/18
Congenital and Pediatric liver diseases Nitika Gupta, M.D. Personal/Professional Financial Relationships with Industry in the past year External Industry Relationships * Equity, stock, or options in biomedical
More informationBiliary Atresia. Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s
Biliary Atresia Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s Biliary Atresia Incidence: 1/8,000-15,000 live births Girls > boys 1.5:1 The most common cause
More informationPrototypes of autoimmune hepatitis and sclerosing cholangitis in childhood
RIUNIONE MONOTEMATICA AISF 2013 Personalizzazione della Cura in Epatologia 17-19 ottobre 2013, PISA Prototypes of autoimmune hepatitis and sclerosing cholangitis in childhood La sottoscritta dichiara di
More informationInterface hepatitis in PBC: Prognostic marker and therapeutic target
Interface hepatitis in PBC: Prognostic marker and therapeutic target Raoul Poupon Service d Hépatologie, Hôpital Saint-Antoine, Paris Faculté de Médecine Pierre & Marie Curie, Paris Key features of
More informationSarah Landes October 23, 2014
Sarah Landes October 23, 2014 A T-cell mediated inflammatory destruction of intralobular bile ducts progressively leading to cholestasis and cirrhosis 9:1 F to M ratio Mostly diagnosed between 30-60 years
More informationPrimary Biliary Cirrhosis
Primary Biliary Cirrhosis What is Primary Biliary Cirrhosis? Primary biliary cirrhosis (PBC) is a chronic liver disease resulting from progressive destruction of the bile ducts in the liver called the
More informationIdiopathic adulthood ductopenia manifesting as jaundice in a young male
Idiopathic adulthood ductopenia manifesting as jaundice in a young male Deepak Jain*,1, H. K. Aggarwal 1, Avinash Rao 1, Shaveta Dahiya 1, Promil Jain 2 1 Department of Medicine, Pt. B.D. Sharma University
More informationCryptogenic Cirrhosis: An Approach To The Diagnosis In The Era Of Molecular Medicine
Cryptogenic Cirrhosis: An Approach To The Diagnosis In The Era Of Molecular Medicine Disclosure of Relevant Financial Relationships USCAP requires that all faculty in a position to influence or control
More informationCanine Chronic Idiopathic Hepatitis
Canine Chronic Idiopathic Hepatitis David C. Twedt DVM, DACVIM Problem Acute Rt rear leg lameness History Probably stepped on by owner s horse Healthy otherwise No medications Physical exam Possible partial
More informationPrimary Sclerosing Cholangitis with Inflammatory Bowel Disease in Korean Children
pissn: 2234-8646 eissn: 2234-8840 http://dx.doi.org/10.5223/pghn.2015.18.4.268 Pediatr Gastroenterol Hepatol Nutr 2015 December 18(4):268-275 Original Article PGHN Primary Sclerosing Cholangitis with Inflammatory
More informationACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society
ACCME/Disclosures The USCAP requires that anyone in a position to influence or control the content of CME disclose any relevant financial relationship WITH COMMERCIAL INTERESTS which they or their spouse/partner
More informationIn the past decade many new transporters have been SPECIAL REPORTS AND REVIEWS
GASTROENTEROLOGY 2006;130:908 925 SPECIAL REPORTS AND REVIEWS Hepatocanalicular Transport Defects: Pathophysiologic Mechanisms of Rare Diseases RONALD P. J. OUDE ELFERINK, COEN C. PAULUSMA, and ALBERT
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationWorld Journal of Gastroenterology
ISSN 1007-9327 (print) ISSN 2219-2840 (online) World Journal of Gastroenterology World J Gastroenterol 2017 August 7; 23(29): 5257-5450 Published by Baishideng Publishing Group Inc S Contents Weekly Volume
More informationCurrent Management of Biliary Atresia. Janeen Jordan, MD PGY5 Surgery Grand Rounds November 19, 2007
Current Management of Biliary Atresia Janeen Jordan, MD PGY5 Surgery Grand Rounds November 19, 2007 Overview Etiology and diagnosis Work-up and management History of Kasai Portoenterostomy Studies Advances
More informationPSC: a care-giver s perspective
PSC: a care-giver s perspective PSC Partners Seeking a Cure; Denver, CO; April 30, 2005 David and Judy Rhodes (father and mother of Steven (19); PSC 07/03; UC 08/03) www.psc-literature.org www.pscpartners.org
More informationRisk stratification in PBC
Risk stratification in PBC Christophe Corpechot Reference Center for Inflammatory Biliary Diseases Saint-Antoine hospital, Paris, France What is currently known (background) PBC : chronic, progressive
More informationAutoimmune Hepatitis. What Drug and for How Long? Hepatology Day May 30 th, 2015
Autoimmune Hepatitis What Drug and for How Long? Rajaa Chatila, MD Associate Professor of Medicine Director, Internal Medicine Residency Program Lebanese American University Hepatology Day May 30 th, 2015
More informationHOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO
HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO The identification of abnormal liver enzymes usually indicates liver damage but rarely
More informationHigh dose UDCA in the Treatment of Primary Sclerosing Cholangitis. Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK
High dose UDCA in the Treatment of Primary Sclerosing Cholangitis Falk Meeting,Freiberg2006 Dr RW Chapman John Radcliffe Hospital Oxford,UK Specific Medical Therapy for PSC Immunosuppressants -prednisolone
More informationImproving the Lives of Patients with Liver Diseases
Improving the Lives of Patients with Liver Diseases Corporate Presentation March 2019 Safe Harbor Statement This presentation contains "forward-looking" statements that involve risks, uncertainties and
More informationFree University of Brussels, *Department of Pediatrics, Universitair Ziekenhuis Brussel, Brussels, Belgium
pissn: 22348646 eissn: 22348840 http://dx.doi.org/10.5223/pghn.2014.17.3.191 Pediatr Gastroenterol Hepatol Nutr 2014 September 17(3):191195 Case Report PGHN Hemorrhagic Diathesis as the Presenting Symptom
More informationIgG4-Negative Autoimmune Pancreatitis with Sclerosing Cholangitis and Colitis: Possible Association with Primary Sclerosing Cholangitis?
CASE REPORT IgG4-Negative Autoimmune Pancreatitis with Sclerosing Cholangitis and Colitis: Possible Association with Primary Sclerosing Cholangitis? Keita Saeki 1, Shigenari Hozawa 1, Naoteru Miyata 1,
More informationCholestatic Expression Pattern of Sinusoidal and Canalicular Organic Anion Transport Systems in Primary Cultured Rat Hepatocytes
Original Articles Cholestatic Expression Pattern of Sinusoidal and Canalicular Organic Anion Transport Systems in Primary Cultured Rat Hepatocytes S. JANE RIPPIN, BRUNO HAGENBUCH, PETER J. MEIER, AND BRUNO
More informationLIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA
LIVER SPECIALTY CONFERENCE USCAP 2016 Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA Nothing to disclose Case History 47-year-old male, long standing ileal
More informationThe regulation of genes that are essential to many
GASTROENTEROLOGY 2005;129:735 740 NEW CONCEPTS IN GASTROENTEROLOGY Nuclear Receptor Ligands: Rational and Effective Therapy for Chronic Cholestatic Liver Disease? JAMES L. BOYER Liver Center, Department
More informationCholestatic liver dysfunction during critical illness
Cholestatic liver dysfunction during critical illness Yoo-Mee Vanwijngaerden Lies Langouche Dieter Mesotten Greet Van den Berghe Department of Cellular and Molecular Medicine Laboratory of Intensive Care
More informationABCB11 Gene Mutations in Children with Progressive Familial Intrahepatic Cholestasis (PFIC) and Low GGT
Med. J. Cairo Univ., Vol. 84, No. 1, March: 249-255, 2016 www.medicaljournalofcairouniversity.net ABCB11 Gene Mutations in Children with Progressive Familial Intrahepatic Cholestasis (PFIC) and Low GGT
More informationPOST TRANSPLANT OUTCOMES IN PSC
POST TRANSPLANT OUTCOMES IN PSC Kidist K. Yimam, MD Medical Director, Autoimmune Liver Disease Program Division of Hepatology and Liver Transplantation California Pacific Medical Center (CPMC) PSC Partners
More informationNEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL
NEW CONCEPTS IN CROHN S DISEASE GLENDON BURRESS, MD PEDIATRIC GASTROENTEROLOGY ROCKFORD, IL CROHN S DISEASE Chronic disease of uncertain etiology Etiology- genetic, environmental, and infectious Transmural
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationNatural history of α-1-atd in children
Natural history of α-1-atd in children Agnieszka Bakuła Dpt of Gastroenterology, Hepatology, Nutrition Disorders and Paediatrics The Children s Memorial Health Institute Warsaw, Poland Topics to be discussed
More informationCholestasis: The ABCs of cellular mechanisms for impaired bile secretion Transporters and genes
HOT TOPICS IN GASTROENTEROLOGY Cholestasis: The ABCs of cellular mechanisms for impaired bile secretion Transporters and genes Eldon A Shaffer MD FRCPC EA Shaffer. Cholestasis: The ABCs of cellular mechanisms
More informationThe importance of pharmacogenetics in the treatment of epilepsy
The importance of pharmacogenetics in the treatment of epilepsy Öner Süzer and Esat Eşkazan İstanbul University, Cerrahpaşa Faculty of Medicine, Department of Pharmacology and Clinical Pharmacology Introduction
More informationABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust
ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE
More information2. Description of the activity
Curricular Components for GI EPA 1. EPA Title Care of infants, children and adolescents with acute and chronic liver diseases, biliary/cholestatic diseases, pancreatic disorders, and those requiring liver
More informationMECHANISMS OF DISEASE. Review Article
Review Article Mechanisms of Disease F RANKLIN H. EPSTEIN, M.D., Editor MOLECULAR PATHOGENESIS OF CHOLESTASIS MICHAEL TRAUNER, M.D., PETER J. MEIER, M.D., AND JAMES L. BOYER, M.D. THE formation of bile
More informationDiagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful?
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2004;2:935 940 Diagnosing Autoimmune Hepatitis in Children: Is the International Autoimmune Hepatitis Group Scoring System Useful? REGAN L. EBBESON* and RICHARD
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationDepartment of Internal Medicine and the Department of Pathology. Wake Forest University
Bile Acid Transporters Paul A. Dawson, Tian Lan, Anuradha Rao Department of Internal Medicine and the Department of Pathology. Wake Forest University School of Medicine. Winston-Salem, NC 27157 Corresponding
More information